Navigation Links
Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
Date:12/3/2010

SAN MATEO, Calif., Dec. 3, 2010 /PRNewswire/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that, as anticipated, on November 30, 2010, the Company received a letter from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market (the "Staff Determination") notifying the Company that, based on its failure to regain compliance with the $1.00 minimum bid price requirement, as set forth in NASDAQ Listing Rule 5550(a)(2), the Company's common stock would be subject to delisting from The NASDAQ Capital Market unless the Company requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel").

The Company intends to request a hearing before the Panel, which will stay any action with respect to the Staff Determination until the Panel renders a decision subsequent to the hearing.  There can be no assurance that following the hearing the Panel will grant the Company's request for continued listing on The NASDAQ Capital Market.

The Staff Determination follows a notification from the Staff dated June 1, 2010, which was disclosed by the Company on June 4, 2010, indicating that the minimum bid price of the Company's common stock had been below $1.00 per share for 30 consecutive business days and that the Company had 180 calendar days, or until November 29, 2010, to regain compliance with the minimum bid price requirement.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rat
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Realigns Management
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
4. Nile Therapeutics Reports 2010 Third Quarter Financial Results
5. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. ImmunGenes Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today
7. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
8. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
9. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
10. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
11. Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015   DocResponse was ranked the ... a peer-reviewed study , "Evaluation of symptom ... published in the July issue of The British ... Medical School researchers determined that performance of online ... correct diagnosis first in standardized patient evaluations more ...
(Date:7/27/2015)... NAMUR , Belgium , July ... MKT: VNRX), a life sciences company focused on developing ... types and other conditions, today announced that it has ... research organization, Global Specimen Solutions, Inc. (GSS), to support ... colorectal cancer tests. Under the agreement, ...
(Date:7/27/2015)... , July 27, 2015 Research and Markets ... "Intraoperative Imaging Market by Type (Intraoperative CT, Intraoperative ... Asia-Pacific, ROW) - Global Forecast to 2019" report ... expected to reach a value of $2.1 Billion by ... of 3.5% during the forecast period. ...
Breaking Medicine Technology:Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 2VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 3VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 4VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 5VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 6VolitionRx Engages Specialty Clinical Research Organization to Support Initial Entry of its NuQ(R) Colorectal Cancer Tests via U.S. CLIA Labs 7Global Intraoperative Imaging (Intraoperative CT, Intraoperative MRI, Intraoperative Ultrasound) Market Forecasts & Trends 2015-2019 2
...  Integware today announced that it has signed a ... PLM Software, a leading global provider of product ... focused for nearly twenty years on extending PLM ... industry. Its platform-neutral development approach enables it to ...
... FLORHAM PARK, N.J., Jan. 25, 2012  Shionogi Inc., the ... announced results from two studies published online today in ... the first study, a randomized, double-blind, placebo-controlled phase III ... 3-16 with problem drooling due to neurologic conditions demonstrated ...
Cached Medicine Technology:Integware Announces Systems Integrator Agreement With Siemens PLM Software 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8
(Date:7/28/2015)... Wilmington, DE (PRWEB) , ... July 28, 2015 , ... ... for 2015. Accounting Today’s annual ranking of Value Added Resellers of ERP Software is ... opportunities they are presented with. This honor represents the second such award in 2015 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Carol McFarland, PT, PhD, ... and demonstration of specific rehabilitation exercises and treatment protocols in the PTA OT ... with an extensive interview conducted by Carol with a board certified neurosurgeon. Specific ...
(Date:7/28/2015)... ... July 28, 2015 , ... Cupertino orthodontist , ... revolutionary orthodontic treatment that allows patients to straighten teeth even without braces. “The ... imaging technology. You wear each set of aligners for about two weeks, removing ...
(Date:7/27/2015)... N.J. (PRWEB) , ... July 28, 2015 , ... Almost ... health plans to offer behavioral health counseling for persons who are obese and those ... happen was less clear. , That mandate will affect any commercial health plan with ...
(Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, such ... volumes that may be early indicators of Alzheimer’s disease and dementia, according to ... vascular risk factors damage the brain and can result in cognitive impairment,” said ...
Breaking Medicine News(10 mins):Health News:Intellitec Solutions Named by Accounting Today as Top 100 Value Added Reseller 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 2Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 3Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 4Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 5Health News:North American Seminars Introduces a New OT PT PTA Online Continuing Education Course on the Treatment of Post Surgical Cervical and Lumbar Spine Patients 6Health News:Cupertino Invisalign Dentist, Dr. Setareh Mozafari, is Now Offering Complimentary Consultations for Invisalign 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3
... affect brain function in adults who have few or ... results of the first study to examine cognitive functioning ... funded by the National Heart, Lung, and Blood Institute ... brain function scores and imaging tests in adult patients ...
... lead to future treatments, researchers say , TUESDAY, May ... that are linked to Alzheimer,s disease and could become ... Genetic variants appear to play an important part in ... with the disease increases a person,s risk. It is ...
... out of every ten pregnant women in the United States are ... the May issue of the American Journal of Obstetrics and ... pregnancy, the study shows that higher doses may be needed for ... Denver School of Medicine, lead author of the study said, "We ...
... facts and don,t recognize the symptoms, U.S. survey reveals , TUESDAY, ... women finds only about one in four women aged 25 to ... , This is important because researchers say it takes longer for ... a stroke, and researchers think lack of awareness about symptoms may ...
... ... hierarchically rather than serially, to deliver highly responsive, customer-oriented presentations. , ... London, UK (PRWEB) ... Designer is now available for Microsoft® Office PowerPoint®. This new software enables ...
... 11, 2010 Complex issues in interventional cardiology ... lab will be the focus of the 19th Annual ... DC. The symposium is being held in conjunction with ... of the Cardiovascular Research Foundation. "Changes are occurring ...
Cached Medicine News:Health News:New study suggests sickle cell disease may affect brain function in adults 2Health News:New study suggests sickle cell disease may affect brain function in adults 3Health News:New Alzheimer's Risk Genes Identified 2Health News:New Alzheimer's Risk Genes Identified 3Health News:Many pregnant women not getting enough vitamin D 2Health News:Women Often Miss Signs of Stroke 2Health News:GMARK Launches World's First Web-Like, PowerPoint Navigation Software 2Health News:Nurse/tech symposium at TCT 2010 will address complex issues in the cardiac cath lab 2
... enzymatic cleaner is a fast-acting ... stubborn deposits in as little ... enzymatic cleaner contains an enzyme ... film on soft contact lenses ...
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box....
Sterile cordless eraser tips, packsize is 10/box....
Medicine Products: